Study #2018-0002
Phase II Study of Combination Ruxolitinib (INCB018424) with Preoperative Chemotherapy for Triple Negative Inflammatory Breast Cancer
MD Anderson Study Status
Not Accepting
Treatment Agent
Ruxolitinib, Paclitaxel, Doxorubicin, Cyclophosphamide
Description
This research study is studying Ruxolitinib as possible treatment for Inflammatory Breast Cancer (IBC). The Following drugs will be use in combination with Ruxolinitinib. * Paclitaxel (also called Taxol) * Doxorubicin also called Adriamycin * Cyclophosphamide, also called Cytoxan
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Inflammatory Breast Cancer (IBC)
Study phase:
Phase II
Physician name:
Azadeh Nasrazadani
Department:
Breast Medical Oncology
For general questions about clinical trials:
1-833-912-3947
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.